Olivan M, Rigau M, Colás E, Garcia M, Montes M, Sequeiros T, Regis L, Celma A, Planas J, Placer J, Reventós J, de Torres I, Doll A, Morote J
Research Unit in Biomedicine and Translational Oncology, Vall d'Hebron Research Institute and Hospital and Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Department of Urology, Vall d'Hebron University Hospital and Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Biomed Res Int. 2015;2015:762178. doi: 10.1155/2015/762178. Epub 2015 Jan 12.
Nowadays prostate cancer is the most common solid tumor in men from industrialized countries and the second leading cause of death. At the ages when PCa is usually diagnosed, mortality related to cardiovascular morbidity is high; therefore, men at risk for PCa frequently receive chronic lipid-lowering and antiplatelet treatment. The aim of this study was to analyze how chronic treatment with statins, aspirin, and their combination influenced the risk of PCa detection. The tumorigenic properties of these treatments were evaluated by proliferation, colony formation, invasion, and migration assays using different PCa cell lines, in order to assess how these treatments act at molecular level. The results showed that a combination of statins and aspirin enhances the effect of individual treatments and seems to reduce the risk of PCa detection (OR: 0.616 (95% CI: 0.467-0.812), P<0.001). However, if treatments are maintained, aspirin (OR: 1.835 (95% CI: 1.068-3.155), P=0.028) or the combination of both drugs (OR: 3.059 (95% CI: 1.894-4.939), P<0.001) represents an increased risk of HGPCa. As observed at clinical level, these beneficial effects in vitro are enhanced when both treatments are administered simultaneously, suggesting that chronic, concomitant treatment with statins and aspirin has a protective effect on PCa incidence.
如今，前列腺癌是工业化国家男性中最常见的实体瘤，也是第二大致死原因。在前列腺癌通常被诊断出的年龄阶段，与心血管疾病相关的死亡率很高；因此，有前列腺癌风险的男性经常接受慢性降脂和抗血小板治疗。本研究的目的是分析他汀类药物、阿司匹林及其联合使用的长期治疗如何影响前列腺癌的检出风险。使用不同的前列腺癌细胞系，通过增殖、集落形成、侵袭和迁移试验评估了这些治疗的致瘤特性，以评估这些治疗在分子水平上的作用方式。结果表明，他汀类药物和阿司匹林联合使用增强了单独治疗的效果，似乎降低了前列腺癌的检出风险（比值比：0.616（95%置信区间：0.467 - 0.812），P<0.001）。然而，如果持续治疗，阿司匹林（比值比：1.835（95%置信区间：1.068 - 3.155），P = 0.028）或两种药物联合使用（比值比：3.059（95%置信区间：1.894 - 4.939），P<0.001）会增加高级别前列腺癌的风险。正如在临床水平观察到的那样，当同时给予两种治疗时，体外的这些有益效果会增强，这表明他汀类药物和阿司匹林的长期联合治疗对前列腺癌的发病率有保护作用。
